pharmaceutical investing Menlo Therapeutics Announces Results from a Phase 2 Trial of Serlopitant for Pruritus Associated with Atopic Dermatitis
pharmaceutical investing Menlo Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline
pharmaceutical investing Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
pharmaceutical investing Dermira’s Share Price Takes a Hit as Two Clinical Trials Failed to Meet Co-Primary Endpoints
Dermira Initiates Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
pharmaceutical investing Immune Pharmaceuticals Announces the launch of REMAIN ™ , an international Overall Survival study with Ceplene® and low dose Proleukin® in REmission MAINtenance in Acute Myeloid Leukemia
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
Element79 Gold Engages Rangefront Mining Services to Prepare NI 43-101 Technical Report on Gold Mountain Project; Site Visit Completed
